J&J Exec Criticizes New Zealand’s Pharmac For Deterring Clinical Trials
This article was originally published in PharmAsia News
Executive Summary
New Zealand’s national drug-purchasing agency, Pharmac, has been criticized as deterring investments in clinical trials in the country, according to an official of Johnson & Johnson’s drug unit, Janssen.